argenx SE (ARGX) extended its recent advance with a strong session, closing at $880.15, up 5.64% and gaining $46.99 from the prior close. That move pushed the stock firmly higher on the chart, reinforcing bullish price action and signaling renewed upside momentum. Trading volume of 339,541 shares came in roughly in line with its 90-day average of 353,639, suggesting this latest surge is being confirmed by steady investor participation rather than an isolated spike. From a short-term perspective, the stock is clearly gaining ground, with buyers showing a willingness to step in at progressively higher levels.
On a longer horizon, ARGX continues to trade in the upper portion of its 52-week range between $510.06 and $934.62, keeping it closer to its recent peak than to its lows. At roughly $54 below its 52-week high set on Dec. 3, 2025, the stock maintains a relatively tight distance to that benchmark, underscoring the strength of its uptrend. Compared with large-cap healthcare and life sciences peers such as AbbVie (ABBV), Merck (MRK), and Pfizer (PFE), argenx’s recent percentage gains stand out, highlighting stronger near-term momentum within the group. Overall, the current tape points to a stock that is advancing with conviction, supported by healthy liquidity and solid positioning near its highs.
Why argenx SE Price is Moving Higher
Investors are looking past the recent 20-day low and weak single-session showing to focus on a powerful fundamental story at argenx SE. The company’s preliminary 2025 results point to a major inflection in its commercial trajectory, with global product net sales surging to $4.15 billion and year-over-year growth of 90%, driven primarily by VYVGART. That strength is echoed in the latest quarterly numbers, where revenue climbed to $947.96 million from $738.41 million, a robust 28.4% sequential increase. Such sustained, high-velocity growth is a key catalyst for renewed bullish sentiment, especially in a biotech environment where many peers are struggling to drive comparable topline expansion.
Momentum is also building around argenx’s strategic roadmap and pipeline depth. Management has laid out clear 2026 priorities centered on multiple Phase 3 readouts for efgartigimod and empasiprubart across four registrational trials in autoimmune indications, giving investors a defined series of potential value-creating catalysts. Additional development milestones — including ARGX-213 entering patient studies, ARGX-124 completing Phase 1, and ARGX-121 advancing into Phase 2 for IgA nephropathy — reinforce the view that argenx is evolving into a diversified immunology platform rather than a single-asset story. The research collaboration with Tensegrity Pharma and option on TSP-101 further bolsters that narrative. Coupled with an established presence alongside large-cap sector names such as AbbVie, Merck, and Pfizer, these favorable developments are helping fuel investor enthusiasm and support the stock’s ongoing move higher.
What is the argenx SE Rating - Should I Buy?
Weiss Ratings assigns ARGX a C rating. Current recommendation is Hold. The stock was upgraded on 8/20/2025, signaling an improving risk/reward profile even though it still sits in the middle of our scale. For investors, a C rating means argenx SE warrants close monitoring rather than aggressive action, but the direction of the rating change is a constructive sign.
Under the surface, several sub-indices lean positive. The Good Growth Index is supported by revenue expanding 97.62%, an exceptionally fast pace that positions the company among the more dynamic names in Health Care. The Good Total Return Index shows that, on a risk-adjusted basis, shareholders have been reasonably rewarded for taking on this name. Combined, these factors help explain why the stock earned an upgrade, even with a forward P/E of 49.24 that embeds high expectations.
Risk management metrics further support the story. The Excellent Solvency Index indicates a strong balance sheet and solid ability to meet financial obligations, an important cushion for a company investing heavily in future growth. Meanwhile, the Fair Efficiency Index and Fair Volatility Index show room for improvement in how capital is deployed and how steadily the stock trades, but they are not outliers for a high-growth biotech.
Within its sector, argenx SE holds the same C (Hold) rating as AbbVie Inc. (ABBV, C) and Merck & Co., Inc. (MRK, C), and stands ahead of Pfizer Inc. (PFE, C-). For investors seeking exposure to an innovative Health Care name with strong growth and balance sheet quality, ARGX’s current rating supports a measured, watchful stance.
About argenx SE
argenx SE is a commercial-stage biotechnology company focused on developing and commercializing innovative antibody-based therapies for autoimmune diseases. Headquartered in Amsterdam, the Netherlands, the company operates across the United States, Japan, China, and other international markets. Its lead products, VYVGART and VYVGART HYTRULO, are already approved to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP), positioning argenx as a meaningful player in the autoimmune neuromuscular disease space. These therapies are built on the company’s expertise in FcRn (neonatal Fc receptor) modulation, a targeted approach designed to reduce pathogenic antibodies that drive many autoimmune conditions.
Beyond its commercial portfolio, argenx maintains a broad and diversified clinical pipeline aimed at expanding the impact of its antibody engineering platforms. Efgartigimod is being developed in multiple indications, including seronegative and ocular gMG, thyroid eye disease, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis, reflecting a strategy to leverage a single core mechanism across a wide range of autoimmune disorders. The company is also advancing empasiprubart for multifocal motor neuropathy, CIDP, delayed graft function, and dermatomyositis, as well as ARGX-119, a MuSK agonist targeting congenital myasthenic syndromes, amyotrophic lateral sclerosis, and spinal muscular atrophy.
argenx further strengthens its competitive position through a network of strategic collaborations with global pharmaceutical and research partners, including AbbVie, Genmab, Chugai, and multiple academic institutions. These collaborations support discovery, development, and potential commercialization of next-generation antibody therapies such as ARGX-109, ARGX-121, ARGX-213, ARGX-118, and others, underscoring the company’s role as an innovative contributor in the global biopharmaceutical and life sciences industry.
Investor Outlook
With a C (Hold) Weiss Rating, argenx SE (ARGX) appears positioned for potential continuation of its recent strength if current momentum aligns with improving fundamentals and sentiment in Health Care. Investors may want to watch how the stock behaves around recent highs and whether sector trends and company execution can support a possible ratings upgrade over time. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--